Short Summary
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Detailed Summary
In a Decision Granting Institution of Inter Partes Review, the Patent Trial and Appeal Board concluded that Imperative Care, Inc. has demonstrated a reasonable likelihood of prevailing on at least one claim of Inari Medical’s U.S. Patent No. 11,974,910 (hemostasis valves). The Board instituted the IPR on all nine challenged claims, citing Grounds 1‑5 that rely on 35 U.S.C. §§ 102 and 103, with prior art references Schaffer, Hartley, and Eller. While the patent owner raised claim‑construction disputes over the term “filament” and argued lack of motivation to combine references, the Board found those arguments unpersuasive at the institution stage. The proceeding now moves forward to trial on the asserted unpatentability grounds.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Imperative Care, Inc. vs Inari Medical, Inc. et al. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Micron Technology, Inc. et al.vsYangtze Memory Technologies Company, Ltd.
Micron Technology successfully instituted PGR against Yangtze Memory Technologies regarding a patent on 3D memory structures. The Board found that the petitioner sufficiently demonstrated obviousness over prior art references Kim and Lee for multiple claims. This moves the dispute into trial phase, raising significant stakes in semiconductor technology licensing.
Revvo Technologies, Inc.vsCerebrum Sensor Technologies, Inc.
The PTAB granted institution of IPR for Revvo Technologies against Cerebrum Sensor Technologies, challenging 26 claims related to sensor assemblies. The Board found a reasonable likelihood that the prior art renders the claims obvious.
Aputure Imaging Industries Co., Ltd.vs--
Aputure Imaging Industries has filed an IPR petition seeking to invalidate all 21 claims of Rotolight's U.S. Patent 10,197,257, arguing anticipation by Pohlert and obviousness over Mueller and Reichow. The petition argues discretionary denial is unwarranted and requests the Board to institute the trial.
Uber Technologies, Inc. et al.vsCarma Technology, Ltd. et al.
Uber has filed an IPR petition seeking to invalidate twelve claims of Carma’s ridesharing patent, arguing they are obvious over prior‑art references Olmi, Paul, and Jarvinen. The petition includes detailed claim constructions and a single obviousness ground under 35 U.S.C. §103.
WHOOP, Inc.vsOmni MedSci, Inc.
WHOOP has filed a Post‑Grant Review petition seeking cancellation of claim 7 of Omni MedSci’s ’790 wearable sensor patent. The petition alleges obviousness over Lisogurski combined with Carlson, Lamego, or Soller, and raises indefiniteness and lack of enablement under § 112. It also invokes collateral estoppel based on prior IPR findings.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.